Apollo Hospitals Enterprise Limited is a Pharmaceuticals company listed on the National Stock Exchange (NSE) with a market capitalisation of ₹1.23 lakh crore. The company reports ROE of 22.5%, a net profit margin of 8.1%. Revenue grew +20.8% year-over-year. Promoter holding stands at 28.4%, with FII participation at 50.6%.
Buying pressure is building (RSI/MACD momentum confirmed). Company earns strong returns on shareholder money (ROE 22.5% — above 15% benchmark). A trend-following indicator is on the bullish side (SuperTrend signal: buy). Short-term oscillator is overheated — entering now means chasing (StochRSI above 80, late entry risk). Yesterday's candle shape suggests sellers took control (⚠️ Doji — bearish pattern detected). Above-average delivery percentage suggests real buying, not just speculation (delivery 56%). Both short and medium-term trend lines are pointing upward — the trend has momentum (rising EMA20 + EMA50). Foreign institutions have been net buyers for 3 consecutive days — sustained institutional demand (✅ FII buying streak).
Apollo Hospitals Enterprise Limited scores 73/100 (High Conviction Research Signal). The strongest signals are Momentum (13/100) and Trend (12/100). The weakest dimension is Institutional Activity (0/100), which warrants monitoring. This reflects JaySense quantitative research scoring only — not investment advice. Consult a SEBI Registered Investment Adviser before making any investment decision.
| Stock | Score | Signal |
|---|---|---|
|
SUNPHARMA
Sun Pharmaceutical Industries Limited
|
84 | High Conviction |
|
AUROPHARMA
Aurobindo Pharma Limited
|
75 | High Conviction |
|
DIVISLAB
Divi's Laboratories Limited
|
72 | High Conviction |
|
CIPLA
Cipla Limited
|
69 | Positive Setup |
|
GLENMARK
Glenmark Pharmaceuticals Limited
|
60 | Positive Setup |